Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.

Sean WhartonSalvatore CalannaMelanie Jane DaviesDror DickerBryan GoldmanIldiko Lingvay Lawrence A LeiterDomenica M RubinoMette ThomsenThomas A WaddenSue D Pedersen

Published in: Diabetes, obesity & metabolism (2021)

GI AEs were more common with semaglutide 2.4 mg than placebo, but typically mild-to-moderate and transient. Semaglutide-induced WL was largely independent of GI AEs.

Keyphrases